Business Wire

Universal DX Initiates Clinical Trial for FDA Approval of Signal-C® Colorectal Cancer Screening Blood Test

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Universal DX (“UDX”), a biotech company dedicated to transforming cancer into a curable disease by detecting it early, today announced closure of the Series B which ...
Oklahoma's News

Blood draw cancer detection test in clinical trials at OU Stephenson Cancer Center

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. OKLAHOMA CITY (KFOR) – A simple blood draw ...
abc27

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass., Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio ...
TMCnet

Pharmacovigilance Market to Reach $26.2 billion, Globally, by 2034 at 12.3% CAGR: Allied Market Research

Pharmacovigilance is increasingly adopted across pharmaceutical companies, regulatory bodies, clinical research organizations, and healthcare providers due to its critical role in monitoring, ...

Mercy Halo Blood Test Shows Promise in Early Lung Cancer Detection: New Study Shows Performance Similar to LDCT with Clinical Complementarity

Mercy BioAnalytics, Inc., a pioneer in blood-based detection of early-stage cancer, today announced data from a ...
ksn.com

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology ...

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. Q32 Bio is ...